<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32737247</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J Nucl Med</ISOAbbreviation></Journal><ArticleTitle>Preclinical Development of <sup>18</sup>F-OF-NB1 for Imaging GluN2B-Containing <i>N</i>-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>259</StartPage><EndPage>265</EndPage><MedlinePgn>259-265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2967/jnumed.120.246785</ELocationID><Abstract><AbstractText>As part of our continuous efforts to develop a suitable <sup>18</sup>F-labeled PET radioligand with improved characteristics for imaging the <i>N</i>-methyl-d-aspartate receptors (NMDARs) subtype 2B (GluN1/2B), we investigated in the current work <i>ortho</i>-fluorinated (OF) and <i>meta</i>-fluorinated (MF) analogs of <sup>18</sup>F-<i>para</i>-fluorinated (PF)-NB1, a 3-benzazepine-based radiofluorinated probe. <b>Methods:</b> OF-NB1 and MF-NB1 were prepared using a multistep synthesis, and their binding affinities toward GluN2B subunits and selectivity over &#x3c3;1 receptors (&#x3c3;1Rs) were determined via competitive binding assays. <sup>18</sup>F-OF-NB1 was synthesized via copper-mediated radiofluorination and was evaluated in Wistar rats by in vitro autoradiography, PET imaging, ex vivo biodistribution, metabolite experiments, and receptor occupancy studies using CP-101,606, an established GluN2B antagonist. To determine in vivo selectivity, <sup>18</sup>F-OF-NB1 was validated in wild-type and &#x3c3;1R knock-out mice. Translational relevance was assessed in autoradiographic studies using postmortem human brain tissues from healthy individuals and ALS patients, the results of which were corroborated by immunohistochemistry. <b>Results:</b> The binding affinity values for OF-NB1 and MF-NB1 toward the GluN2B subunits were 10.4 &#xb1; 4.7 and 590 &#xb1; 36 nM, respectively. For &#x3c3;1R binding, OF-NB1 and MF-NB1 exhibited inhibition constants of 410 and 2,700 nM, respectively. OF-NB1, which outperformed MF-NB1, was radiolabeled with <sup>18</sup>F to afford <sup>18</sup>F-OF-NB1 in more than 95% radiochemical purity and molar activities of 192 &#xb1; 33 GBq/&#x3bc;mol. In autoradiography experiments, <sup>18</sup>F-OF-NB1 displayed a heterogeneous and specific binding in GluN2B subunit-rich brain regions such as the cortex, striatum, hypothalamus, and hippocampus. PET imaging studies in Wistar rats showed a similar heterogeneous uptake, and no brain radiometabolites were detected. A dose-dependent blocking effect was observed with CP-101,606 (0.5-15 mg/kg) and resulted in a 50% receptor occupancy of 8.1 &#x3bc;mol/kg. Postmortem autoradiography results revealed lower expression of the GluN2B subunits in ALS brain tissue sections than in healthy controls, in line with immunohistochemistry results. <b>Conclusion:</b><sup>18</sup>F-OF-NB1 is a highly promising PET probe for imaging the GluN2B subunits of the <i>N-</i>methyl-d-aspartate receptor. It possesses utility for receptor occupancy studies and has potential for PET imaging studies in ALS patients and possibly other brain disorders.</AbstractText><CopyrightInformation>&#xa9; 2021 by the Society of Nuclear Medicine and Molecular Imaging.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Hazem</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallimann</LastName><ForeName>Rahel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haider</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosseini</LastName><ForeName>Vahid</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory of Applied Mechanobiology, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Z&#xfc;rich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruber</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robledo</LastName><ForeName>Marvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Thi A N</ForeName><Initials>TAN</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herde</LastName><ForeName>Adrienne M&#xfc;ller</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iten</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Viola</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory of Applied Mechanobiology, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Z&#xfc;rich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schibli</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>W&#xfc;nsch</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical and Medicinal Chemistry, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu</LastName><ForeName>Linjing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ametamey</LastName><ForeName>Simon M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121001">NR2B NMDA receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GluN2B-subunit</Keyword><Keyword MajorTopicYN="N">NMDA</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">receptor occupancy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32737247</ArticleId><ArticleId IdType="doi">10.2967/jnumed.120.246785</ArticleId><ArticleId IdType="pii">jnumed.120.246785</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>